NasdaqCM:TGTXBiotechs
Did Phase 3 Subcutaneous BRIUMVI Enrollment Just Redefine TG Therapeutics' (TGTX) MS Strategy?
TG Therapeutics recently completed enrollment in a Phase 3 trial evaluating two subcutaneous dosing regimens of its anti-CD20 therapy BRIUMVI for relapsing forms of multiple sclerosis, comparing them with the currently approved intravenous schedule.
This milestone moves the company closer to potentially offering a self-administered alternative within the anti-CD20 segment, a shift that could be important in a market increasingly focused on treatment convenience and administration...